Indoco Remedies is trading at RS. 317.25, up by 7.20 points or 2.32% from its previous close of RS. 310.05 on the BSE.

The stock opened at RS. 327.75 and has touched an intraday high of RS. 327.75 and a low of RS. 311.15 so far, with 2499 shares traded on the counter.

This BSE group 'B' stock, with a face value of RS. 2, recorded a 52-week high of RS. 385.50 on September 12, 2024, and a 52-week low of RS. 190.00 on February 28, 2025. In the past week, the scrip has traded between RS. 339.60 and RS. 308.60. The current market capitalization of the company stands at RS. 2901.66 crore.

The promoter holding in the company is 58.90%, while institutional and non-institutional investors hold 19.99% and 21.11% respectively.

In a significant development, Indoco Remedies has received the Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility — Goa Plant II, located at L32, 33, and 34, Verna Industrial Estate, South Goa.

The EU GMP certification confirms that the facility complies with stringent European manufacturing standards. Indoco reaffirmed its commitment to adhering to current Good Manufacturing Practices (cGMP) and consistently delivering high-quality pharmaceutical products to its global customer base.

Indoco Remedies is actively involved in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India.